Is MYGN or NEO more undervalued in 2026?

CirclFi compares Myriad Genetics, Inc. (MYGN) and NeoGenomics, Inc. (NEO) using 13 institutional-grade valuation models. MYGN has a Quality of Company score of 6.6/10 while NEO scores 6.8/10.

Which is a better buy — MYGN or NEO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MYGN and NEO valuations compare?

MYGN at $4.22 and NEO at $10.19 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MYGN vs NEO Valuation Comparison 2026 — Intrinsic Value Analysis

MYGN

Diagnostics & Research

Myriad Genetics, Inc.

Quality

6.6

out of 10

Value Trap

SAFE

Price

$4.22

Last close

Models

12/13

Active

NEO

Diagnostics & Research

NeoGenomics, Inc.

Quality

6.8

out of 10

Value Trap

LOW

Price

$10.19

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	MYGN Fair Value	MYGN Upside	NEO Fair Value	NEO Upside
Bayesian DCF	Intrinsic	$0.06	-98.5%	$0.46	-95.5%
Earnings Power Value	Intrinsic	$16.62	+293.9%	$5.57	-41.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MYGN vs NEO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MYGN vs NEO — Which Stock Is More Undervalued?

NEO scores higher with a 6.8/10 quality rating vs MYGN's 6.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Myriad Genetics, Inc. (MYGN) and NeoGenomics, Inc. (NEO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MYGN currently trades at $4.22 with a QOC of 6.6/10, while NEO trades at $10.19 with a QOC of 6.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).